دنبال کردن
Ashley Otter, PhD
Ashley Otter, PhD
نام‌های دیگرAshley David Otter, Ash Otter
UK Health Security Agency
ایمیل تأیید شده در ukhsa.gov.uk - صفحهٔ اصلی
عنوان
نقل شده توسط
نقل شده توسط
سال
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study
VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ...
The Lancet 397 (10286), 1725-1735, 2021
7542021
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)
VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ...
The Lancet 397 (10283), 1459-1469, 2021
6652021
Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection
V Hall, S Foulkes, F Insalata, P Kirwan, A Saei, A Atti, E Wellington, ...
New England Journal of Medicine 386 (13), 1207-1220, 2022
5452022
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
C Manisty, AD Otter, TA Treibel, Á McKnight, DM Altmann, T Brooks, ...
The Lancet 397 (10279), 1057-1058, 2021
4302021
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
CJ Reynolds, C Pade, JM Gibbons, DK Butler, AD Otter, K Menacho, ...
Science 372 (6549), 1418-1423, 2021
3332021
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
L Swadling, MO Diniz, NM Schmidt, OE Amin, A Chandran, E Shaw, ...
Nature 601 (7891), 110-117, 2022
3222022
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
M Ainsworth, M Andersson, K Auckland, JK Baillie, E Barnes, S Beer, ...
The Lancet Infectious Diseases 20 (12), 1390-1400, 2020
3182020
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
CJ Reynolds, C Pade, JM Gibbons, AD Otter, KM Lin, D Muñoz Sandoval, ...
Science 377 (6603), eabq1841, 2022
2762022
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ...
The Lancet 399 (10320), 143-151, 2022
2262022
Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection
CJ Reynolds, L Swadling, JM Gibbons, C Pade, MP Jensen, MO Diniz, ...
Science immunology 5 (54), eabf3698, 2020
1942020
COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing
T Peto, D Affron, B Afrough, A Agasu, M Ainsworth, A Allanson, K Allen, ...
EClinicalMedicine 36, 2021
1822021
Extended interval BNT162b2 vaccination enhances peak antibody generation
H Parry, R Bruton, C Stephens, C Bentley, K Brown, G Amirthalingam, ...
npj Vaccines 7 (1), 14, 2022
1462022
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a …
R Lazarus, S Baos, H Cappel-Porter, A Carson-Stevens, M Clout, ...
The Lancet 398 (10318), 2277-2287, 2021
1202021
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
H Parry, G McIlroy, R Bruton, M Ali, C Stephens, S Damery, A Otter, ...
Blood cancer journal 11 (7), 136, 2021
1182021
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups
HJ Whitaker, RSM Tsang, R Byford, NJ Andrews, J Sherlock, PS Pillai, ...
Journal of Infection 84 (5), 675-683, 2022
1112022
Prior infection with SARS-CoV-2 boosts and broadens Ad26. COV2. S immunogenicity in a variant-dependent manner
R Keeton, SI Richardson, T Moyo-Gwete, T Hermanus, MB Tincho, ...
Cell host & microbe 29 (11), 1611-1619. e5, 2021
1052021
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
CJ Reynolds, JM Gibbons, C Pade, KM Lin, DM Sandoval, F Pieper, ...
Science 375 (6577), 183-192, 2022
1012022
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ...
The Lancet 399 (10325), 665-676, 2022
752022
Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people
H Parry, R Bruton, C Stephens, K Brown, G Amirthalingam, A Otter, ...
Immunity & Ageing 18, 1-8, 2021
732021
Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection
C Manisty, TA Treibel, M Jensen, A Semper, G Joy, RK Gupta, ...
EBioMedicine 65, 2021
672021
سیستم در حال حاضر قادر به انجام عملکرد نیست. بعداً دوباره امتحان کنید.
مقاله‌ها 1–20